Literature DB >> 3431961

An immunohistological evaluation of Pseudomonas aeruginosa pulmonary infection in two patients with cystic fibrosis.

D P Speert1, J E Dimmick, G B Pier, J M Saunders, R E Hancock, N Kelly.   

Abstract

Pseudomonas aeruginosa is the principal pulmonary pathogen in patients with cystic fibrosis. All attempts to date to prevent or eradicate P. aeruginosa infections in these patients have been unsuccessful. Vaccination against P. aeruginosa has been proposed as a preventive strategy but it has not been adequately evaluated. The purpose of this study was to determine whether P. aeruginosa, present in the lungs of patients with cystic fibrosis, express surface antigens similar to those grown in vitro; this issue is of critical importance when choosing bacterial products as vaccine candidates. Lung sections from two patients who died of the pulmonary complications of cystic fibrosis were studied. Bacteria, both in lung sections and isolated from the lung sections and grown in vitro, reacted strongly with polyclonal and monoclonal antibodies against P. aeruginosa mucoid exopolysaccharide and outer membrane proteins F and H2; this suggested that these antigens are surface exposed in vivo. It was also found that bacteria in both lung sections were associated in situ with IgG, IgA, and C3 but not with IgM or C4.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3431961     DOI: 10.1203/00006450-198712000-00026

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  Signals, regulatory networks, and materials that build and break bacterial biofilms.

Authors:  Ece Karatan; Paula Watnick
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

2.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

3.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.

Authors:  S S Pedersen; A Kharazmi; F Espersen; N Høiby
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function.

Authors:  M Hentzer; G M Teitzel; G J Balzer; A Heydorn; S Molin; M Givskov; M R Parsek
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

5.  Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

Review 6.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 7.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

8.  Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA.

Authors:  J C Boucher; J Martinez-Salazar; M J Schurr; M H Mudd; H Yu; V Deretic
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

9.  Surface characteristics of Pseudomonas aeruginosa grown in a chamber implant model in mice and rats.

Authors:  N M Kelly; A Bell; R E Hancock
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

10.  Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.

Authors:  G B Pier; D DesJardin; M Grout; C Garner; S E Bennett; G Pekoe; S A Fuller; M O Thornton; W S Harkonen; H C Miller
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.